BioNTech SE - ADR

+2.78 (+2.13%)
Regulatory, Earnings Announcements

EMA CHMP Backs Authorising Additional Adapted Version Of Comirnaty In Vaccinated People

Published: 09/12/2022 15:15 GMT
BioNTech SE - ADR (BNTX) - Ema Adapted Vaccine Targeting Ba.
4 and Ba.
5 Omicron Variants and Original Sars-cov-2 Recommended for Approval.
Ema: Comirnaty Original/omicron Ba.
4-5 is for Use in People Aged 12-yrs& Above Who Have Received at Least Primary Course of Vaccination Against Covid.
Ema: Clinical Studies With Comirnaty Original/omicron Ba.
4-5 Are Ongoing and Chmp Will Receive Emerging Clinical Data As They Are Being Generated.
Ema Says Chmp Opinion on Comirnaty Original/omicron Ba.
4-5 Will Now Be Sent to European Commission, Which Will Adopt a Final Decision.
Ema: Chmp Concluded Comirnaty Original/omicron Ba.
4-5 Expected to Be More Effective Than Comirnaty at Triggering Immune Response Against Ba.
4, Ba.
5 Subvariants.
Further Company Coverage: Pfen ((reuters.
Revenue is expected to be $2.35 Billion
Adjusted EPS is expected to be $3.62

Next Quarter Revenue Guidance is expected to be $3.91 Billion
Next Quarter EPS Guidance is expected to be $7.85

More details on our Analysts Page.